WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for ...

TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extending its cash runway into 2027 ...

Clinical-stage biotechnology company TScan Therapeutics, Inc. (TCRX) Thursday announced that it has entered into a securities ...

TScan Therapeutics (TCRX) entered into a securities purchase agreement with Lynx1 Capital Management and an investment fund advised by Lynx1 for the sale of approximately $30M of pre-funded warrants ...

Key Insights Significantly high institutional ownership implies TScan Therapeutics' stock price is sensitive to ...

TScan Therapeutics shares jumped 23% in premarket trading after a $30 million registered direct offering. Shares were trading around $3.58. The stock is down about 50% on the year.

Wedbush reissued their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research report sent to investors on Monday morning,RTT News reports. The firm currently has a ...

TScan Therapeutics secures a $52.5 million term loan from Silicon Valley Bank to enhance financial flexibility and support cancer therapies. TScan Therapeutics, Inc. has announced a term loan ...

WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T ...

WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...

About TScan Therapeutics, Inc. TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...